142 related articles for article (PubMed ID: 34951143)
21. Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
Madorsky Rowdo FP; Barón A; Gallagher SJ; Hersey P; Emran AA; Von Euw EM; Barrio MM; Mordoh J
Int J Oncol; 2020 Jun; 56(6):1429-1441. PubMed ID: 32236593
[TBL] [Abstract][Full Text] [Related]
22. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
[TBL] [Abstract][Full Text] [Related]
23. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V; Berger W; Paulitschke P; Hofstätter E; Knapp B; Dingelmaier-Hovorka R; Födinger D; Jäger W; Szekeres T; Meshcheryakova A; Bileck A; Pirker C; Pehamberger H; Gerner C; Kunstfeld R
Mol Cancer Ther; 2015 Mar; 14(3):757-68. PubMed ID: 25612618
[TBL] [Abstract][Full Text] [Related]
25. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
26. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation.
Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS
Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149
[TBL] [Abstract][Full Text] [Related]
28. Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM.
Rohrbeck L; Gong JN; Lee EF; Kueh AJ; Behren A; Tai L; Lessene G; Huang DC; Fairlie WD; Strasser A; Herold MJ
Cell Death Differ; 2016 Dec; 23(12):2054-2062. PubMed ID: 27689874
[TBL] [Abstract][Full Text] [Related]
29. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
30. Nrf2/Keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.
Hintsala HR; Jokinen E; Haapasaari KM; Moza M; Ristimäki A; Soini Y; Koivunen J; Karihtala P
Anticancer Res; 2016 Apr; 36(4):1497-506. PubMed ID: 27069125
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells.
Beck D; Niessner H; Smalley KS; Flaherty K; Paraiso KH; Busch C; Sinnberg T; Vasseur S; Iovanna JL; Drießen S; Stork B; Wesselborg S; Schaller M; Biedermann T; Bauer J; Lasithiotakis K; Weide B; Eberle J; Schittek B; Schadendorf D; Garbe C; Kulms D; Meier F
Sci Signal; 2013 Jan; 6(260):ra7. PubMed ID: 23362240
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.
Ji Z; Kumar R; Taylor M; Rajadurai A; Marzuka-Alcalá A; Chen YE; Njauw CN; Flaherty K; Jönsson G; Tsao H
Clin Cancer Res; 2013 Aug; 19(16):4383-91. PubMed ID: 23812671
[TBL] [Abstract][Full Text] [Related]
33. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.
Bauer D; Werth F; Nguyen HA; Kiecker F; Eberle J
Cell Death Dis; 2017 Feb; 8(2):e2594. PubMed ID: 28151482
[TBL] [Abstract][Full Text] [Related]
34. Everolimus selectively targets vemurafenib resistant BRAF
Ruzzolini J; Peppicelli S; Andreucci E; Bianchini F; Margheri F; Laurenzana A; Fibbi G; Pimpinelli N; Calorini L
Cancer Lett; 2017 Nov; 408():43-54. PubMed ID: 28826720
[TBL] [Abstract][Full Text] [Related]
35. Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells.
Mologni L; Costanza M; Sharma GG; Viltadi M; Massimino L; Citterio S; Purgante S; Raman H; Pirola A; Zucchetti M; Piazza R; Gambacorti-Passerini C
Neoplasia; 2018 May; 20(5):467-477. PubMed ID: 29605720
[TBL] [Abstract][Full Text] [Related]
36. BRAF
Feng L; Li J; Bu X; Zuo Y; Shen L; Qu X
Biochem Biophys Res Commun; 2020 Mar; 524(1):28-35. PubMed ID: 31980175
[TBL] [Abstract][Full Text] [Related]
37. Mitochondrial oxidative stress is the Achille's heel of melanoma cells resistant to Braf-mutant inhibitor.
Corazao-Rozas P; Guerreschi P; Jendoubi M; André F; Jonneaux A; Scalbert C; Garçon G; Malet-Martino M; Balayssac S; Rocchi S; Savina A; Formstecher P; Mortier L; Kluza J; Marchetti P
Oncotarget; 2013 Nov; 4(11):1986-98. PubMed ID: 24161908
[TBL] [Abstract][Full Text] [Related]
38. BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
Paoluzzi L; Hanniford D; Sokolova E; Osman I; Darvishian F; Wang J; Bradner JE; Hernando E
Cancer Med; 2016 Jun; 5(6):1183-93. PubMed ID: 27169980
[TBL] [Abstract][Full Text] [Related]
39. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.
Wang J; Chen J; Miller DD; Li W
Mol Cancer Ther; 2014 Jan; 13(1):16-26. PubMed ID: 24249714
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of resistance to vemurafenib leads to interleukin-10 production through an aberrant activation of Akt in a melanoma cell line.
Inozume T; Tsunoda T; Morisaki T; Harada K; Shirasawa S; Kawamura T
J Dermatol; 2018 Dec; 45(12):1434-1439. PubMed ID: 30222203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]